Senti Biosciences Holdings (SNTI) Capital Leases (2023)

Senti Biosciences Holdings (SNTI) posted quarterly Capital Leases of $25000.0 for Q3 2023, down 48.98% quarter-over-quarter from $49000.0 in Q2 2023.

Senti Biosciences Holdings (SNTI) Capital Leases (2023) Analysis & Trends

Senti Biosciences Holdings' Capital Leases history runs 1 years deep, the most recent figure standing at $25000.0 for Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Senti Biosciences Holdings	12.06 Mn	12.06 Mn	-

Download Data